In tirzepatide body composition analysis from SURMOUNT-1 study, reductions occurred in both fat mass and lean mass, and post-hoc analyses described the proportion of weight loss as fat versus lean mass across subgroups, demonstrating that lean mass loss is a consistent feature across GLP-1 and dual GLP-1/GIP agonists.
factualpending
Speaker
Dr. Amin DadgarEvidence Quote
“In tirzepatide body composition analysis from SURMOUNT-1 study, reductions occurred in both fat mass and lean mass. Post-hoc analyses described the proportion of weight loss as fat versus lean mass across subgroups.”
Created: 8/12/2026, 6:40:36 PM
Your notes
Loading notes...